Table 1.
Summary of the cohort, tumour, and treatment characteristics of the included studies.
| Variable | Number providing data | Median estimate | Range | ||
|---|---|---|---|---|---|
| Studies | Patients | ||||
| Cohort characteristics | |||||
| No., all tests | 12 | 641 | 53.4 | 16–142 | |
| Age (years) | 12 | 641 | 50.5 | 24–71 | |
| pCR (prevalence) | 12 | 245 | 40.7% | 16.9–85.0% | |
| non-pCR (prevalence) | 12 | 396 | 59.3% | 15.0–83.1% | |
| Tumour characteristics | |||||
| Stage | I | 2 | 20 | 11.9% | 6.3–17.5% |
| II | 7 | 235 | 42.2% | 10.0–68.3% | |
| III | 8 | 210 | 58.5% | 7.9–90.0% | |
| IVa | 3 | 9 | 4.3% | 3.4–6.3% | |
| Histology | IDC | 8 | 390 | 84.5% | 39.6–96.4% |
| ILC | 7 | 56 | 14.9% | 1.8–58.5% | |
| MC | 5 | 5 | 3.1% | 1.8–6.2% | |
| Other | 2 | 3 | 2.3% | 1.1–5.8% | |
| Receptor | ER (+) | 5 | 149 | 48.0% | 4.3–75% |
| PR (+) | 4 | 121 | 51.0% | 36.6–68.8% | |
| HER-2 (+) | 6 | 176 | 33.6% | 17.1–78.2% | |
| LA | 2 | 10 | 16.5% | 7.9–28.6% | |
| LB | 3 | 46 | 54.5% | 28.6–100% | |
| Triple (−) | 5 | 65 | 24.5% | 12.5–33.3% | |
ER = oestrogen receptor; PR = progesterone receptor; HER2 = human epidermal growth factor receptor 2; IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma; MC = mucinous carcinoma; LA = luminal A; LB = luminal B; NAC = neoadjuvant chemotherapy; NR = not reported; pCR = pathologic complete response; Triple (−) = Triple negative.